サンプル依頼リスト カート
  • English
  • Korean
表紙：子宮がん治療薬・診断薬の世界市場規模調査・予測、がんタイプ別、製品別、地域別分析、2023～2030年
市場調査レポート
商品コード
1355696

子宮がん治療薬・診断薬の世界市場規模調査・予測、がんタイプ別、製品別、地域別分析、2023～2030年

Global Uterine Cancer Therapeutics & Diagnostics Market Size Study & Forecast, by Type of Cancer, by Product and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
子宮がん治療薬・診断薬の世界市場規模調査・予測、がんタイプ別、製品別、地域別分析、2023～2030年
出版日: 2023年09月10日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の子宮がん治療薬・診断薬市場は、予測期間2023～2030年にかけて6%以上の健全な成長率で成長すると予測されます。

子宮体がん治療薬・診断薬とは、子宮体がん（子宮内膜がんとしても知られる）を管理・発見するために用いられるさまざまな治療法や診断法を指します。子宮体がんは、子宮の組織、主に子宮内膜と呼ばれる子宮の内側に発生するがんの一種です。医療費の増加と子宮がん治療に関する意識の高まりが、全世界の子宮がん治療薬・診断薬市場の成長を促進すると予想されます。

子宮体がんの有病率の増加は、子宮体がん治療薬・診断薬市場の成長を促進すると予測されています。Cancer.netが2023年に発表した報告書によると、2020年に子宮体がんと診断された人は世界で約41万7,367人でした。また、子宮体がんの90％以上は子宮内膜（子宮の内膜）で発見されると推定されています。子宮内膜がんの発生率の増加は、主に女性の肥満の増加に起因しており、子宮がん治療薬・診断薬市場を牽引する重要な要因となっています。さらに、医薬品開発活動における技術革新の増加や医療分野における技術進歩の高まりは、今後数年間の市場成長に様々な有利な見通しを提示しています。しかし、子宮体がんの治療に関連する高額な費用と、抗がん剤の臨床試験で観察される低い成功率が、2023～2030年の予測期間を通じて市場の成長を阻害しています。

子宮がん治療薬・診断薬の世界市場調査において考慮した主要地域は以下の通りです：アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカ。北米は、ブランド製品の優位性とこの地域の疾患有病率の増加により、2022年の市場を独占しました。子宮体がんの罹患率の増加と一般住民の意識の高まりが、この地域の市場成長を促進する主な要因です。米国がん協会によると、米国では2020年に約65,620例の子宮体がんが新たに発生すると推定されています。アジア太平洋は、予測期間中に最も高いCAGRで成長すると予想されています。診断における急速な技術進歩や新技術の急速な採用などの要因が、この地域の市場成長を規定しています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 子宮がん治療薬・診断薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 子宮体がん治療薬・診断薬の世界市場力学

  • 子宮がん治療薬・診断薬市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 医療支出の増加
      • 子宮がんに対する認識の高まり
    • 市場の課題
      • 子宮がん治療薬・診断薬の高コスト
      • 抗がん剤臨床試験の成功率の低さ
    • 市場機会
      • 製剤開発の進歩
      • 技術的進歩の増加

第4章 子宮がん治療薬・診断薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 子宮がん治療薬・診断薬の世界市場：がんタイプ別

  • 市場スナップショット
  • 子宮がん治療薬・診断薬の世界市場：がんタイプ別、実績・ポテンシャル分析
  • 子宮がん治療薬・診断薬の世界市場：がんタイプ別、推定・予測、2020～2030年
  • 子宮がん治療薬・診断薬市場、サブセグメント分析
    • 子宮内膜腺がん
    • 腺扁平上皮がん
    • 乳頭状漿液がん
    • 子宮肉腫

第6章 子宮体がん治療薬・診断薬の世界市場：製品別

  • 市場スナップショット
  • 子宮がん治療薬・診断薬の世界市場：製品別、実績・ポテンシャル分析
  • 子宮がん治療薬・診断薬の世界市場：製品別、推定・予測、2020～2030年
  • 子宮がん治療薬・診断薬市場、サブセグメント別分析
    • 治療薬
    • 診断薬

第7章 子宮がん治療薬・診断薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 子宮がん治療薬・診断薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • がんの種類、推定・予測、2020～2030年
      • 製品、推定・予測、2020～2030年
    • カナダ
  • 欧州の子宮がん治療薬・診断薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • アジア太平洋の子宮がん治療薬・診断薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカの子宮がん治療薬・診断薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他の中東およびアフリカ

第8章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • AbbVie Inc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Ability Pharma SA
    • AstraZeneca PLC
    • BioMerieux S.A.
    • Danaher Corporation
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc

第9章 調査プロセス

  • 調査プロセス
    • データ鉱業
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Uterine Cancer Therapeutics & Diagnostics Market, report scope
  • TABLE 2. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Type of Cancer 2020-2030 (USD Billion)
  • TABLE 4. Global Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by Product 2020-2030 (USD Billion)
  • TABLE 5. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Uterine Cancer Therapeutics & Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. U.S. Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67. South Africa Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. RoMEA Uterine Cancer Therapeutics & Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Uterine Cancer Therapeutics & Diagnostics Market
  • TABLE 70. List of primary sources, used in the study of global Uterine Cancer Therapeutics & Diagnostics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Uterine Cancer Therapeutics & Diagnostics Market, research methodology
  • FIG 2. Global Uterine Cancer Therapeutics & Diagnostics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Uterine Cancer Therapeutics & Diagnostics Market, key trends 2022
  • FIG 5. Global Uterine Cancer Therapeutics & Diagnostics Market, growth prospects 2023-2030
  • FIG 6. Global Uterine Cancer Therapeutics & Diagnostics Market, porters 5 force model
  • FIG 7. Global Uterine Cancer Therapeutics & Diagnostics Market, pest analysis
  • FIG 8. Global Uterine Cancer Therapeutics & Diagnostics Market, value chain analysis
  • FIG 9. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Uterine Cancer Therapeutics & Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Uterine Cancer Therapeutics & Diagnostics Market, regional snapshot 2020 & 2030
  • FIG 15. North America Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Uterine Cancer Therapeutics & Diagnostics Market is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2023-2030. Uterine cancer therapeutics and diagnostics refer to the various treatments and diagnostic methods used to manage and detect uterine cancer, also known as endometrial cancer. Uterine cancer is a type of cancer that develops in the tissues of the uterus, primarily in the lining of the uterus called the endometrium. Increasing healthcare expenditure and growing awareness regarding uterine cancer treatment is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market across the globe

The increasing prevalence of uterine cancer is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market. According to a report published by Cancer.net in 2023, approximately 417,367 individuals worldwide were diagnosed with uterine cancer in the year 2020. Also, it is estimated that over 90% of uterine cancers are found in the endometrium, which is the lining of the uterus. The growing incidence of endometrium carcinoma, primarily attributed to increasing obesity among women, is a key factor driving the Uterine Cancer Therapeutics & Diagnostics Market. Furthermore, the increasing innovation in drug development activities, as well as rising technological advancements in the healthcare sector are presenting various lucrative prospects for the market growth over the anticipated years. However, the high cost associated with the treatment of Uterine Cancer and the low success rate observed in clinical trials for cancer drugs stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Uterine Cancer Therapeutics & Diagnostics Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. The increasing incidence of uterine cancer and the rising awareness among the general population are the key factors driving the growth of the market in this region. According to the American Cancer Society, approximately 65,620 new cases of uterine body cancer were estimated in the United States in the year 2020. Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as rapid technological advancements in diagnostics and the rapid adoption of new technologies are stipulating the regional market growth

Major market players included in this report are:

  • AbbVie Inc.
  • Ability Pharma SA
  • AstraZeneca PLC
  • BioMerieux S.A.
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc

Recent Developments in the Market:

  • In April 2022, Roche received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA MMR RxDx Panel, designed for advanced or recurrent endometrial cancer patients. The panel detects microsatellite instability (MSI) and mismatch repair (MMR) deficiencies, which are molecular mechanisms that help correct errors during DNA replication. This testing enables the identification of patients who are eligible for treatment with JEMPERLI (dostarlimab-gxly), a monotherapy anti-PD1 immunotherapy developed by GlaxoSmithKline (GSK) and approved by the FDA.

Global Uterine Cancer Therapeutics & Diagnostics Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type of Cancer, Product, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Cancer:

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

By Product:

  • Therapeutics
  • Diagnostics

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Uterine Cancer Therapeutics & Diagnostics Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Uterine Cancer Therapeutics & Diagnostics Market, by Type of Cancer, 2020-2030 (USD Billion)
    • 1.2.3. Uterine Cancer Therapeutics & Diagnostics Market, by Product, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Uterine Cancer Therapeutics & Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Uterine Cancer Therapeutics & Diagnostics Market Dynamics

  • 3.1. Uterine Cancer Therapeutics & Diagnostics Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing healthcare expenditure
      • 3.1.1.2. Growing awareness of uterine cancer
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Uterine Cancer Therapeutics & Diagnostics
      • 3.1.2.2. Low success rate observed in clinical trials for cancer drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in Formulation of drug development
      • 3.1.3.2. Increasing technological advancements

Chapter 4. Global Uterine Cancer Therapeutics & Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Uterine Cancer Therapeutics & Diagnostics Market, by Type of Cancer

  • 5.1. Market Snapshot
  • 5.2. Global Uterine Cancer Therapeutics & Diagnostics Market by Type of Cancer, Performance - Potential Analysis
  • 5.3. Global Uterine Cancer Therapeutics & Diagnostics Market Estimates & Forecasts by Type of Cancer 2020-2030 (USD Billion)
  • 5.4. Uterine Cancer Therapeutics & Diagnostics Market, Sub Segment Analysis
    • 5.4.1. Endometrial Adenocarcinoma
    • 5.4.2. Adenosquamous Carcinoma
    • 5.4.3. Papillary Serous Carcinoma
    • 5.4.4. Uterine Sarcoma

Chapter 6. Global Uterine Cancer Therapeutics & Diagnostics Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Uterine Cancer Therapeutics & Diagnostics Market by Product, Performance - Potential Analysis
  • 6.3. Global Uterine Cancer Therapeutics & Diagnostics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 6.4. Uterine Cancer Therapeutics & Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Therapeutics
    • 6.4.2. Diagnostics

Chapter 7. Global Uterine Cancer Therapeutics & Diagnostics Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Uterine Cancer Therapeutics & Diagnostics Market, Regional Market Snapshot
  • 7.4. North America Uterine Cancer Therapeutics & Diagnostics Market
    • 7.4.1. U.S. Uterine Cancer Therapeutics & Diagnostics Market
      • 7.4.1.1. Type of Cancer breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Product breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Uterine Cancer Therapeutics & Diagnostics Market
  • 7.5. Europe Uterine Cancer Therapeutics & Diagnostics Market Snapshot
    • 7.5.1. U.K. Uterine Cancer Therapeutics & Diagnostics Market
    • 7.5.2. Germany Uterine Cancer Therapeutics & Diagnostics Market
    • 7.5.3. France Uterine Cancer Therapeutics & Diagnostics Market
    • 7.5.4. Spain Uterine Cancer Therapeutics & Diagnostics Market
    • 7.5.5. Italy Uterine Cancer Therapeutics & Diagnostics Market
    • 7.5.6. Rest of Europe Uterine Cancer Therapeutics & Diagnostics Market
  • 7.6. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market Snapshot
    • 7.6.1. China Uterine Cancer Therapeutics & Diagnostics Market
    • 7.6.2. India Uterine Cancer Therapeutics & Diagnostics Market
    • 7.6.3. Japan Uterine Cancer Therapeutics & Diagnostics Market
    • 7.6.4. Australia Uterine Cancer Therapeutics & Diagnostics Market
    • 7.6.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market
    • 7.6.6. Rest of Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market
  • 7.7. Latin America Uterine Cancer Therapeutics & Diagnostics Market Snapshot
    • 7.7.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market
    • 7.7.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market
  • 7.8. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
    • 7.8.1. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market
    • 7.8.2. South Africa Uterine Cancer Therapeutics & Diagnostics Market
    • 7.8.3. Rest of Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. AbbVie Inc.
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Ability Pharma SA
    • 8.3.3. AstraZeneca PLC
    • 8.3.4. BioMerieux S.A.
    • 8.3.5. Danaher Corporation
    • 8.3.6. Eli Lilly and Company
    • 8.3.7. F. Hoffmann-La Roche Ltd
    • 8.3.8. GlaxoSmithKline PLC
    • 8.3.9. Johnson & Johnson Services, Inc.
    • 8.3.10. Merck & Co., Inc

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption